Q4 2025 Saniona AB Earnings Call Transcript

Feb 26, 2026 / 10:00 AM GMT

Release Date Price: €2.12 (-1.63%)

Transcript

Key Points

Positve

Saniona AB (FRA:30S) strengthened its financial position in 2025, ending the year with approximately 581 million crowns in cash.
The company secured significant pharmaceutical partnerships, including an exclusive license agreement with Jazz Pharmaceuticals and a collaboration with Acadia.
Saniona AB (FRA:30S) advanced three CNS programs towards clinical development, focusing on epilepsy and depression.
The company successfully raised 150 million crowns through G04 financing, with a 97.6% exercise rate, indicating strong shareholder support.
Saniona AB (FRA:30S) expanded its leadership team and operational capacity, increasing headcount from 22 to 34 employees and enhancing capabilities in clinical development and other areas.

Negative

Saniona AB (FRA:30S) reported a Q4 loss of SEK41 million, attributed to the absence of milestone payments during the quarter.
Operating expenses increased in 2025 due to higher personnel and program costs, with expectations of further increases in 2026.
The company anticipates needing additional funding to complete phase 2 programs, as current cash reserves are not sufficient for full phase 2 completion.
The approval process for tizofensine in Mexico has been ongoing for several years, with no final approvals yet, limiting its strategic importance compared to the CNS pipeline.
Saniona AB (FRA:30S) faces competition in the obesity market, with new GLP-1 analogs offering similar efficacy to tizofensine, impacting its commercial opportunity.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SANION.ST - Saniona AB
Q4 2025 Saniona AB Earnings Call
Feb 26, 2026 / 10:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Okay, hello and welcome to this live queue with Sonny Wana regarding the Q4 report. First off, we will have a presentation by the company and the CFO Jonas Tlou and CEO Thomas Feltus, and after that, we will have a Q&A. So please, Sunny I start with your presentation.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
So good morning everyone and thank you for joining our Q4 and full year 2025 investor update.

So 2025 has been an important and transformational year for Sanyona.

We strengthened our financial position, advanced 3 different shaded CNS programs towards the clinic,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.